The Fleming Fund's Phase I Report Launch Event

Following the publication of our Phase I Report on Tuesday 26th April, the Fleming Fund hosted a launch event the following Wednesday. The aim of the launch event was to announce HMG approval for the Fleming Fund until 2025, showcase our new publication and share our partners’ work.

The event kicked off with an introduction from the UK Special Envoy on AMR, Professor Dame Sally Davies. She emphasised the importance of using data to understand and take ownership of the AMR challenge, and empower “healthcare workers with the tools they need to drive solutions”. Dame Sally’s presentation concluded with a “resounding warning to the world that there is no time to wait”. She continued:

It is time for us all to step up and speak out against the insidious, silent AMR pandemic”.

A Summary of the Phase I Report

A representative from the Fleming Fund was then invited to dive into the contents of the Phase I Report. This included short presentations from the following contributors:

There were two main themes from the presentations: the importance of data, and collaboration. Speaking on the role of fellows in generating and using data in the Fleming Fund’s fellowship scheme, Toby Leslie emphasised that “data is the lynchpin for decision-making and action”. Morgan Jeannin was optimistic that countries’ ambition to tackle AMR is “reflected in the growing quality of data provided each year” in the OIE Antimicrobial Use (AMU) Global Database, summarised on pages 40 and 41 of the report.

On collaboration, Victoria Rutter attributed a large part of the success of the Commonwealth Pharmacists for Antimicrobial Stewardship (CwPAMS) scheme to “the power of partnership”. This was concurred by Morgan, who called for partners to “continue to work collaboratively in the fight against AMR”.

Panel Discussion and Q&A

The stage was set for a wider discussion on tackling the AMR problem. Mediated by the chair of DHSC’s Technical Advisory Group for the Fleming Fund, Nicholas Feasey, the following panellists presented on their contribution to the report before responding to questions from attendees:

It was great to hear some examples of how the Fleming Fund is making a difference in-country. Josh Francis mentioned the “striking” results in Timor-Leste, outlined in more detail on pages 20 and 21 of the report. Ayesha Rasheed presented on the role of the Fleming Fund in Pakistan, who are working with the Pakistan National Institute of Health (NIH) and WHO in an example of “true partnership”.

Baucau Hospital Laboratory in Timor-Leste, which is supported by the Fleming Fund.

Satyajit Sarkar and Jorge Pinto Ferreira spoke to wider themes of AMR surveillance, specifically on driving policy and behaviour change. Satyajit called for policymakers to “pay greater attention to the seemingly intangible”. This includes improving incentives and increasing trust amongst stakeholders to share data and building greater political and societal ownership of AMR. Jorge, presenting on his colleague Emmanuel Kabali’s article in the report, emphasised the need to creating a culture of knowledge sharing to change behaviour, as “knowledge is only good insofar as it is shared and disseminated”.

The questions that we were unable to answer in the event have been added to the end of this post.

Reflection and wrap-up

Although our contributors shared their many achievements, it’s apparent that there’s still a lot to do in the AMR surveillance space.

The event was an opportunity to share the Fleming Fund’s achievements throughout Phase I, but also invite collaboration to ensure that our investments are sustainable. If you would be interested in working together on an area of the programme, please email

The full document is available here

View docx (114.59 KB)

More Like This

To mark One Health Day, we revisit the holistic concept spanning human, animal, and environmental health, which is one of the Fleming Fund’s guiding principles.

A plaque on the side of the Saint Mary’s Hospital in Paddington, London, UK, commemorates the discovery of penicillin, the first antibiotic, in 1928. Fungal spores, blown by the wind, landed on Sir Alexander Fleming's Petri dishes killing the bacteria he was growing leading to a revolution in medicine.